Status:

UNKNOWN

p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage

Lead Sponsor:

Shenzhen SiBiono GeneTech Co.,Ltd

Conditions:

Neoplasms

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

This is multicenter, open-label, randomized, active-controled, phase IV study of local direct intra-tumor injection of rAd-p53 monotherapy, with concurrent chemotherapy , with concurrent radiotherapy,...

Detailed Description

Primary objectives of this study is to determine the efficacy profiles of rAd-p53 intra-tumor injection alone, with concurrent chemotherapy, with concurrent radiotherapy, or combination with surgery f...

Eligibility Criteria

Inclusion

  • Advanced stages of head and neck malignant tumors (stage III and VI)
  • At least one target tumor can be injected with study drug, the largest diameter greater than 2 cm
  • Histologically confirmed head and neck malignant tumors
  • No prior chemotherapy, radiotherapy or biological tumor therapy in 2 weeks
  • Age: 18-85 years old
  • Expected to survive more 12 weeks
  • ECOG:0-2
  • Neutrophils≥1.5×109/L,Platelet≥ 80×109/L, Hb≥80g/L, bilitubin≤2mg/dl,ALT and AST ≤2×institutional upper limit of normal, Cr ≤1.5×institutional upper limit of normal,coagulation tests (PTT and INR) within normal range
  • Subject provided signed informed consent

Exclusion

  • Hypersensitive to study drug
  • Tumor(s) locate very close to important blood vessels and nerves, which affect injection
  • With a coagulation and bleeding disorder
  • With uncontrolled, intercurrent illness including but limited to symptomatic neurological illness, symptomatic congestive heart failure, unstable angina pectoris, significant pulmonary disease or hypoxia, or psychiatric illness
  • Local infection close to injection site or systemic infection
  • Pregnant or lactating
  • Principle investigator consider not suitable

Key Trial Info

Start Date :

May 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2013

Estimated Enrollment :

1200 Patients enrolled

Trial Details

Trial ID

NCT00894153

Start Date

May 1 2009

End Date

June 1 2013

Last Update

April 9 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of oral and maxillofacial surgery, Huaxi university of medical science

Chendu, Shichuan, China, 610041

p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage | DecenTrialz